• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Research Briefing on 2-Chloro-4-(oxetan-3-yloxy)pyrimidin-5-amine (CAS: 1701598-01-7) and Its Recent Advances in Chemical Biology and Pharmaceutical Research

2-Chloro-4-(oxetan-3-yloxy)pyrimidin-5-amine (CAS: 1701598-01-7) has emerged as a promising scaffold in medicinal chemistry, particularly in the development of kinase inhibitors and targeted therapies. Recent studies have highlighted its unique structural features, combining a pyrimidine core with an oxetane moiety, which confers enhanced solubility and metabolic stability compared to traditional heterocyclic compounds. This molecular architecture has attracted significant attention from pharmaceutical researchers exploring novel therapeutic agents for oncology and inflammatory diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's potential as a selective inhibitor of cyclin-dependent kinases (CDKs), particularly showing nanomolar activity against CDK2 and CDK4. The oxetane substitution at the 4-position was found to significantly improve cellular permeability while maintaining target engagement, addressing a common challenge in kinase inhibitor development. Molecular docking simulations revealed that the oxetanyloxy group forms critical hydrogen bonds with the kinase hinge region, explaining the observed selectivity profile.

In synthetic chemistry advancements, researchers have developed novel synthetic routes to 2-Chloro-4-(oxetan-3-yloxy)pyrimidin-5-amine that improve yield and scalability. A recent patent (WO2023056421) describes a three-step synthesis from commercially available 2,4-dichloropyrimidin-5-amine, featuring a key oxetane coupling under mild conditions. This process innovation has enabled gram-scale production with >90% purity, facilitating further pharmacological evaluation.

Pharmacokinetic studies in preclinical models have shown favorable ADME properties for derivatives of this scaffold. The oxetane moiety appears to mitigate rapid glucuronidation observed with similar compounds lacking this feature, while maintaining acceptable CYP450 inhibition profiles. These findings, reported in the European Journal of Pharmaceutical Sciences (2024), suggest this chemical class may overcome common drug metabolism challenges associated with pyrimidine-based therapeutics.

Emerging applications extend beyond oncology, with recent research exploring the scaffold's utility in targeting RNA-modifying enzymes. A Nature Chemical Biology publication (2024) identified 2-Chloro-4-(oxetan-3-yloxy)pyrimidin-5-amine derivatives as allosteric modulators of METTL3/METTL14, the m6A methyltransferase complex, opening new avenues for epigenetic drug discovery. The oxetane modification was crucial for achieving cellular activity in this context, suggesting broader applicability of this structural motif in chemical biology.

Ongoing clinical translation efforts include structure-activity relationship (SAR) optimization to improve potency and selectivity. Computational fragment-based drug design approaches are being employed to explore substitutions at the 2-chloro and 5-amino positions while preserving the critical oxetane pharmacophore. These developments position 2-Chloro-4-(oxetan-3-yloxy)pyrimidin-5-amine as a versatile building block for next-generation targeted therapies with potential advantages in drug-like properties.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)